TY  - JOUR
AU  - Widjaja, Liam
AU  - Hornfeck, Johannes
AU  - Siegmund, Sophie C
AU  - Gildehaus, Franz J
AU  - Schmidt-Hegemann, Nina-Sophie
AU  - Wenter, Vera
AU  - Sheikh, Gabriel T
AU  - Klimek, Konrad
AU  - Casuscelli, Jozefina
AU  - Stief, Christian G
AU  - Zacherl, Mathias J
AU  - Werner, Rudolf A
TI  - Refining the clinical utility of [177Lu]Lu/[225Ac]Ac-PSMA tandem RLT in patients with metastatic castration resistant prostate cancer.
JO  - European journal of nuclear medicine and molecular imaging
VL  - nn
SN  - 1619-7070
CY  - Heidelberg [u.a.]
PB  - Springer-Verl.
M1  - DKFZ-2025-02262
SP  - nn
PY  - 2025
N1  - epub
AB  - This study aimed to evaluate the efficacy and safety of Lutetium-177/Actinium-225 prostate-specific membrane antigen tandem radioligand therapy ([177Lu]Lu/[225Ac]Ac-PSMA tandem RLT) and to explore clinical and imaging-based predictors of treatment response to support individualized patient selection.This retrospective, single-center study included 23 patients with mCRPC who underwent Fluor-18 ([18F]F)-PSMA-1007 positron emission tomography/computed tomography (PET/CT) and subsequent tandem RLT. Whole-body tumor segmentation on PET/CT and standard laboratory values were acquired before treatment initiation. Primary endpoint was partial response (PR), defined as either a decline in prostate specific antigen of ≥ 50
KW  - PSMA-RLT (Other)
KW  - Prostate cancer (Other)
KW  - Tandem RLT (Other)
KW  - Targeted alpha therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41174098
DO  - DOI:10.1007/s00259-025-07632-1
UR  - https://inrepo02.dkfz.de/record/305612
ER  -